Figure 5.

Other α₂-adrenoceptor agonists, oxymetazoline (Oxy; 1 mmol·L⁻¹) and clonidine (Clo; 0.5 mmol·L⁻¹), also reversibly reduce compound action potential (CAP) peak amplitudes. (A, B) Effects of α₂ agonists (A: Oxy; B: Clo) on CAP peak amplitudes. (Aa, Ba) Recordings of CAPs in the control, after 6, 12 and 20 min of exposure to α₂ adrenoceptor agonists (A: Oxy; B: Clo) and thereafter 12, 30 and 60 min in the absence of α₂ adrenoceptor agonists (A: Oxy; B: Clo). Upper insets in (Aa) and (Ba) show the chemical structures of oxymetazoline and clonidine, respectively (see Westfall and Westfall, 2006). (Ab, Bb) Average time courses of changes in CAP peak amplitudes following exposure to α₂ adrenoceptor agonists (Ab: Oxy; Bb: Clo) for 20 min, relative to that before exposure, obtained from four (Ab) or five (Bb) sciatic nerves.